Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Ouno is dedicated to simplifying business travel. Their application provides luxurious, on-demand rides for executives, seamlessly connecting clients with their preferred drivers. By 2023, Ouno has generated £1.1 million in revenue since the app's launch, although it has experienced a negative EBITDA of £350,000 during this period.
days to go:
Expired
investment:
£411,778
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
A thought leadership media platform working with trusted experts to bring innovative advancements to organisations through journalism. The Future Shapers aims to re-imagine how information is delivered globally and the ways it can help small to large communities innovate further, avoiding the use of advertisers and paywalls.
days to go:
Expired
investment:
£41,610
Myn is an innovative source-to-pay platform driven by AI, aiming to establish a seamless network connecting companies, workers, and recruiters. Their end-to-end solution encompasses intelligent talent sourcing, self-service talent acquisition, fully funded payrolling services, digital compliance solutions, job boards, and enticing employee benefits.
days to go:
Expired
investment:
£939,520
Nimbli is a London-based Fintech company which is promoting financial inclusion in East Africa by using innovative technology. It is currently working in strategic partnership with a Major African Bank to launch its mobile application in 1Q 2019. Through its mobile application, Nimbli will provide better financial services to small and medium enterprises (SMEs) and help in reducing the number of people who don’t have credit access to zero.
days to go:
Expired
investment:
£65,670
Currently, the self-employed have fewer admissions to financial services than their employed counterparts do. Hatch aims to give sole traders free-to-use access to real-time credit scores that will allow lenders to make more informed decisions when invoice funding. The company also offers digitising of tax files, one of the most time-consuming admin burdens. Revenue is generated via affiliate fees to those who wish to introduce and facilitate Hatch on their platforms. A beta for 5k users will be launching soon, with half the slots already filled.
days to go:
Expired
investment:
£115,000
